BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35040083)

  • 1. Anti-Ro52 Autoantibody Is Common in Systemic Autoimmune Rheumatic Diseases and Correlating with Worse Outcome when Associated with interstitial lung disease in Systemic Sclerosis and Autoimmune Myositis.
    Chan EKL
    Clin Rev Allergy Immunol; 2022 Oct; 63(2):178-193. PubMed ID: 35040083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Utility of Separate Anti-Ro60 and Anti-Ro52/TRIM21 Antibody Detection in Autoimmune Diseases.
    Robbins A; Hentzien M; Toquet S; Didier K; Servettaz A; Pham BN; Giusti D
    Front Immunol; 2019; 10():444. PubMed ID: 30915082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of the clinical significance of Ro52/TRIM21 antibody and specific antinuclear antibody patterns by indirect immunofluorescence.
    Liu K; Liao Y; Li P; Shi J
    J Pak Med Assoc; 2024 Feb; 74(2):236-242. PubMed ID: 38419219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Ro52 and/or anti-Ro60 immune reactivity: autoantibody and disease associations.
    Zampeli E; Mavrommati M; Moutsopoulos HM; Skopouli FN
    Clin Exp Rheumatol; 2020; 38 Suppl 126(4):134-141. PubMed ID: 32083547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ro52/TRIM21 - From host defense to autoimmunity.
    Holwek E; Opinc-Rosiak A; Sarnik J; Makowska J
    Cell Immunol; 2023; 393-394():104776. PubMed ID: 37857191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Ro60 Seropositivity Determines Anti-Ro52 Epitope Mapping in Patients With Systemic Sclerosis.
    Gkoutzourelas A; Liaskos C; Mytilinaiou MG; Simopoulou T; Katsiari C; Tsirogianni A; Daoussis D; Scheper T; Meyer W; Bogdanos DP; Sakkas LI
    Front Immunol; 2018; 9():2835. PubMed ID: 30581434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun.
    Popovic K; Brauner S; Ek M; Wahren-Herlenius M; Nyberg F
    Lupus; 2007; 16(1):10-7. PubMed ID: 17283579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical associations of the positive anti Ro52 without Ro60 autoantibodies: undifferentiated connective tissue diseases.
    Murng SHK; Thomas M
    J Clin Pathol; 2018 Jan; 71(1):12-19. PubMed ID: 28663326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ro52, Ro60 and La IgG autoantibody levels and Ro52 IgG subclass profiles longitudinally throughout pregnancy in congenital heart block risk pregnancies.
    Strandberg L; Salomonsson S; Bremme K; Sonesson S; Wahren-Herlenius M
    Lupus; 2006; 15(6):346-53. PubMed ID: 16830880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to Cytosolic 5'-Nucleotidase 1A in Primary Sjögren's Syndrome and Systemic Lupus Erythematosus.
    Rietveld A; van den Hoogen LL; Bizzaro N; Blokland SLM; Dähnrich C; Gottenberg JE; Houen G; Johannsen N; Mandl T; Meyer A; Nielsen CT; Olsson P; van Roon J; Schlumberger W; van Engelen BGM; Saris CGJ; Pruijn GJM
    Front Immunol; 2018; 9():1200. PubMed ID: 29922285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the role and clinical utility of anti-Ro52/TRIM21 in systemic autoimmunity.
    Lee AYS
    Rheumatol Int; 2017 Aug; 37(8):1323-1333. PubMed ID: 28417151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of antigen-specific anti-cytomegalovirus antibody reactivity in patients with systemic sclerosis and concomitant anti-Ro52 antibodies.
    Gkoutzourelas A; Liaskos C; Simopoulou T; Katsiari C; Efthymiou G; Scheper T; Meyer W; Tsirogianni A; Tsigalou C; Dardiotis E; Daoussis D; Sakkas LI; Bogdanos DP
    Rheumatol Int; 2020 Oct; 40(10):1689-1699. PubMed ID: 32681396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management.
    Decker P; Moulinet T; Pontille F; Cravat M; De Carvalho Bittencourt M; Jaussaud R
    Autoimmun Rev; 2022 Mar; 21(3):103013. PubMed ID: 34896652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latest update on the Ro/SS-A autoantibody system.
    Schulte-Pelkum J; Fritzler M; Mahler M
    Autoimmun Rev; 2009 Jun; 8(7):632-7. PubMed ID: 19393201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Ro52/TRIM21 antibodies are associated with aberrant inflammatory circuits in patients with systemic autoimmune rheumatic diseases.
    Amezcua-Guerra LM; Pérez-García LF; Jiménez-Rojas V; Márquez-Velasco R; Silveira LH
    Gac Med Mex; 2023; 159(1):55-64. PubMed ID: 36930561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA association of anti-Ro60 and anti-Ro52 antibodies in Sjögren's syndrome.
    Ricchiuti V; Isenberg D; Muller S
    J Autoimmun; 1994 Oct; 7(5):611-21. PubMed ID: 7530962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death.
    Espinosa A; Zhou W; Ek M; Hedlund M; Brauner S; Popovic K; Horvath L; Wallerskog T; Oukka M; Nyberg F; Kuchroo VK; Wahren-Herlenius M
    J Immunol; 2006 May; 176(10):6277-85. PubMed ID: 16670339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer.
    Bogdanos DP; Gkoutzourelas A; Papadopoulos V; Liaskos C; Patrikiou E; Tsigalou C; Saratziotis A; Hajiioannou J; Scheper T; Meyer W; Sakkas LI; Papandreou C
    Clin Chim Acta; 2021 Oct; 521():199-205. PubMed ID: 34245687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures.
    Rhodes DA; Ihrke G; Reinicke AT; Malcherek G; Towey M; Isenberg DA; Trowsdale J
    Immunology; 2002 Jun; 106(2):246-56. PubMed ID: 12047754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Different Profiles of anti-Ro Antibodies in Connective Tissue Diseases.
    Yang HT; Hong XP; Guo JW; Zhong XL; Liao R; Liu CL; Liu LX; Li K; Chen YL; Liu DZ
    J Immunol Res; 2023; 2023():9195157. PubMed ID: 36741231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.